Published in Blood Weekly, November 4th, 2004
Researchers in the Netherlands examined data from "all completed studies evaluating pentasaccharides - synthetically derived, selective inhibitors of activated factor X - in prophylaxis in major orthopedic surgery and the treatment of venous thromboembolism."
"Venous thromboembolism is a disorder with considerable morbidity when left untreated," explained M. Nijkeuter and coauthors at Leiden University. "The pentasaccharides fondaparinux and idraparinux are the first of a new class of synthetic selective inhibitors of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.